fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Silodosin

8 Limited Use · 2 not a benefit

Auro-Silodosin · DIN 02478501 · 4 mg · capsule

Limited Use, Reason for Use code 351, 352 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 351, 352 required
Write on scriptone applicable Reason for Use code, 351 or 352 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 351, 352
Reason for Use code 351 For the management of benign prostatic hyperplasia where six weeks of treatment with other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have been ineffective. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 352 For the management of benign prostatic hyperplasia where other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have produced intolerable side effects. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Auro-Silodosin · DIN 02478501 Manufacturer: Auro Pharma Inc.; listing date 2022-04-29 Health Canada: Marketed since 2022-02-16 · brand AURO-SILODOSIN · ATC G04CA04 SILODOSIN · form Capsule · route Oral · ingredients SILODOSIN 4 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Silodosin: Formulary list price $0.47 per unit (the source does not state the unit; exact figure $0.4742). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02478501)

Source record
DIN 02478501: Auro-Silodosin Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000678; group id 961; item number 2281; lccId 00229; manufacturer id AUR Source form: Cap; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4742; ministry $0.4742 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02478501 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96929
Interchangeable products
Jamp Silodosin · DIN 02539519 · $0.4742 PMS-Silodosin · DIN 02517779 · $0.4742 Rapaflo · DIN 02361663 · not recorded Sandoz Silodosin · DIN 02475421 · $0.4742
Shortage status: resolved shortage (ended October 28, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02478501
Shortage record checked October 6, 2026

Jamp Silodosin · DIN 02539519 · 4 mg · capsule

Limited Use, Reason for Use code 351, 352 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 351, 352 required
Write on scriptone applicable Reason for Use code, 351 or 352 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 351, 352
Reason for Use code 351 For the management of benign prostatic hyperplasia where six weeks of treatment with other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have been ineffective. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 352 For the management of benign prostatic hyperplasia where other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have produced intolerable side effects. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Jamp Silodosin · DIN 02539519 Manufacturer: Jamp Pharma Corporation; listing date 2024-06-28 Health Canada: Marketed since 2024-05-22 · brand JAMP SILODOSIN · ATC G04CA04 SILODOSIN · form Capsule · route Oral · ingredients SILODOSIN 4 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Silodosin: Formulary list price $0.47 per unit (the source does not state the unit; exact figure $0.4742). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02539519)

Source record
DIN 02539519: Jamp Silodosin Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000678; group id 961; item number 2281; lccId 00229; manufacturer id JPC Source form: Cap; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4742; ministry $0.4742 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02539519 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102827
Interchangeable products
Auro-Silodosin · DIN 02478501 · $0.4742 PMS-Silodosin · DIN 02517779 · $0.4742 Rapaflo · DIN 02361663 · not recorded Sandoz Silodosin · DIN 02475421 · $0.4742
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02539519
Shortage record checked October 6, 2026

PMS-Silodosin · DIN 02517779 · 4 mg · capsule

Limited Use, Reason for Use code 351, 352 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 351, 352 required
Write on scriptone applicable Reason for Use code, 351 or 352 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 351, 352
Reason for Use code 351 For the management of benign prostatic hyperplasia where six weeks of treatment with other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have been ineffective. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 352 For the management of benign prostatic hyperplasia where other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have produced intolerable side effects. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Silodosin · DIN 02517779 Manufacturer: Pharmascience Inc.; listing date 2021-11-30 Health Canada: Marketed since 2021-10-21 · brand PMS-SILODOSIN · ATC G04CA04 SILODOSIN · form Capsule · route Oral · ingredients SILODOSIN 4 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Silodosin: Formulary list price $0.47 per unit (the source does not state the unit; exact figure $0.4742). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02517779)

Source record
DIN 02517779: PMS-Silodosin Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000678; group id 961; item number 2281; lccId 00229; manufacturer id PMS Source form: Cap; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4742; ministry $0.4742 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02517779 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100713
Interchangeable products
Auro-Silodosin · DIN 02478501 · $0.4742 Jamp Silodosin · DIN 02539519 · $0.4742 Rapaflo · DIN 02361663 · not recorded Sandoz Silodosin · DIN 02475421 · $0.4742
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02517779
Shortage record checked October 6, 2026

Sandoz Silodosin · DIN 02475421 · 4 mg · capsule

Limited Use, Reason for Use code 351, 352 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 351, 352 required
Write on scriptone applicable Reason for Use code, 351 or 352 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 351, 352
Reason for Use code 351 For the management of benign prostatic hyperplasia where six weeks of treatment with other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have been ineffective. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 352 For the management of benign prostatic hyperplasia where other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have produced intolerable side effects. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Sandoz Silodosin · DIN 02475421 Manufacturer: Sandoz Canada Inc.; listing date 2021-03-29 Health Canada: Marketed since 2021-01-08 · brand SANDOZ SILODOSIN · ATC G04CA04 SILODOSIN · form Capsule · route Oral · ingredients SILODOSIN 4 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Silodosin: Formulary list price $0.47 per unit (the source does not state the unit; exact figure $0.4742). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02475421)

Source record
DIN 02475421: Sandoz Silodosin Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000678; group id 961; item number 2281; lccId 00229; manufacturer id SDZ Source form: Cap; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4742; ministry $0.4742 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02475421 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96581
Interchangeable products
Auro-Silodosin · DIN 02478501 · $0.4742 Jamp Silodosin · DIN 02539519 · $0.4742 PMS-Silodosin · DIN 02517779 · $0.4742 Rapaflo · DIN 02361663 · not recorded
Shortage status: resolved shortage (ended April 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02475421
Shortage record checked October 6, 2026

Auro-Silodosin · DIN 02478528 · 8 mg · capsule

Limited Use, Reason for Use code 351, 352 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 351, 352 required
Write on scriptone applicable Reason for Use code, 351 or 352 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 351, 352
Reason for Use code 351 For the management of benign prostatic hyperplasia where six weeks of treatment with other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have been ineffective. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 352 For the management of benign prostatic hyperplasia where other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have produced intolerable side effects. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Auro-Silodosin · DIN 02478528 Manufacturer: Auro Pharma Inc.; listing date 2022-04-29 Health Canada: Marketed since 2022-02-16 · brand AURO-SILODOSIN · ATC G04CA04 SILODOSIN · form Capsule · route Oral · ingredients SILODOSIN 8 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Silodosin: Formulary list price $0.47 per unit (the source does not state the unit; exact figure $0.4742). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02478528)

Source record
DIN 02478528: Auro-Silodosin Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000679; group id 961; item number 2282; lccId 00229; manufacturer id AUR Source form: Cap; strength: 8mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4742; ministry $0.4742 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02478528 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96930
Interchangeable products
Jamp Silodosin · DIN 02539527 · $0.4742 PMS-Silodosin · DIN 02517787 · $0.4742 Rapaflo · DIN 02361671 · not recorded Sandoz Silodosin · DIN 02475448 · $0.4742
Shortage status: resolved shortage (ended September 13, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02478528
Shortage record checked October 6, 2026

Jamp Silodosin · DIN 02539527 · 8 mg · capsule

Limited Use, Reason for Use code 351, 352 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 351, 352 required
Write on scriptone applicable Reason for Use code, 351 or 352 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 351, 352
Reason for Use code 351 For the management of benign prostatic hyperplasia where six weeks of treatment with other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have been ineffective. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 352 For the management of benign prostatic hyperplasia where other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have produced intolerable side effects. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Jamp Silodosin · DIN 02539527 Manufacturer: Jamp Pharma Corporation; listing date 2024-06-28 Health Canada: Marketed since 2024-05-22 · brand JAMP SILODOSIN · ATC G04CA04 SILODOSIN · form Capsule · route Oral · ingredients SILODOSIN 8 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Silodosin: Formulary list price $0.47 per unit (the source does not state the unit; exact figure $0.4742). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02539527)

Source record
DIN 02539527: Jamp Silodosin Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000679; group id 961; item number 2282; lccId 00229; manufacturer id JPC Source form: Cap; strength: 8mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4742; ministry $0.4742 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02539527 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102828
Interchangeable products
Auro-Silodosin · DIN 02478528 · $0.4742 PMS-Silodosin · DIN 02517787 · $0.4742 Rapaflo · DIN 02361671 · not recorded Sandoz Silodosin · DIN 02475448 · $0.4742
Shortage status: resolved shortage (ended August 1, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02539527
Shortage record checked October 6, 2026

PMS-Silodosin · DIN 02517787 · 8 mg · capsule

Limited Use, Reason for Use code 351, 352 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 351, 352 required
Write on scriptone applicable Reason for Use code, 351 or 352 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 351, 352
Reason for Use code 351 For the management of benign prostatic hyperplasia where six weeks of treatment with other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have been ineffective. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 352 For the management of benign prostatic hyperplasia where other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have produced intolerable side effects. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
PMS-Silodosin · DIN 02517787 Manufacturer: Pharmascience Inc.; listing date 2021-11-30 Health Canada: Marketed since 2021-10-21 · brand PMS-SILODOSIN · ATC G04CA04 SILODOSIN · form Capsule · route Oral · ingredients SILODOSIN 8 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Silodosin: Formulary list price $0.47 per unit (the source does not state the unit; exact figure $0.4742). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02517787)

Source record
DIN 02517787: PMS-Silodosin Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000679; group id 961; item number 2282; lccId 00229; manufacturer id PMS Source form: Cap; strength: 8mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4742; ministry $0.4742 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02517787 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100714
Interchangeable products
Auro-Silodosin · DIN 02478528 · $0.4742 Jamp Silodosin · DIN 02539527 · $0.4742 Rapaflo · DIN 02361671 · not recorded Sandoz Silodosin · DIN 02475448 · $0.4742
Shortage status: resolved shortage (ended August 23, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02517787
Shortage record checked October 6, 2026

Sandoz Silodosin · DIN 02475448 · 8 mg · capsule

Limited Use, Reason for Use code 351, 352 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 351, 352 required
Write on scriptone applicable Reason for Use code, 351 or 352 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 351, 352
Reason for Use code 351 For the management of benign prostatic hyperplasia where six weeks of treatment with other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have been ineffective. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 352 For the management of benign prostatic hyperplasia where other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have produced intolerable side effects. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Sandoz Silodosin · DIN 02475448 Manufacturer: Sandoz Canada Inc.; listing date 2021-03-29 Health Canada: Marketed since 2021-01-08 · brand SANDOZ SILODOSIN · ATC G04CA04 SILODOSIN · form Capsule · route Oral · ingredients SILODOSIN 8 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Silodosin: Formulary list price $0.47 per unit (the source does not state the unit; exact figure $0.4742). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02475448)

Source record
DIN 02475448: Sandoz Silodosin Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000679; group id 961; item number 2282; lccId 00229; manufacturer id SDZ Source form: Cap; strength: 8mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.4742; ministry $0.4742 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02475448 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96582
Interchangeable products
Auro-Silodosin · DIN 02478528 · $0.4742 Jamp Silodosin · DIN 02539527 · $0.4742 PMS-Silodosin · DIN 02517787 · $0.4742 Rapaflo · DIN 02361671 · not recorded
Shortage status: resolved shortage (ended April 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02475448
Shortage record checked October 6, 2026

Rapaflo · DIN 02361663 · 4 mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2021-12-06 — choose a marketed DIN from the same-category list.Discontinued December 6, 2021 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2021-12-06 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2021-12-06 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 351, 352
Reason for Use code 351 For the management of benign prostatic hyperplasia where six weeks of treatment with other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have been ineffective. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 352 For the management of benign prostatic hyperplasia where other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have produced intolerable side effects. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Rapaflo · DIN 02361663 Manufacturer: Watson Laboratories Inc.; listing date 2013-02-28 Health Canada: Cancelled post market since 2021-12-06 · brand RAPAFLO · ATC G04CA04 SILODOSIN · form Capsule · route Oral · ingredients SILODOSIN 4 MG · company Allergan inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Rapaflo: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02361663)

Source record
DIN 02361663: Rapaflo Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 920000678; group id 961; item number 2281; lccId 00229; manufacturer id WAT Source form: Cap; strength: 4mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02361663 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84673
Interchangeable products
Auro-Silodosin · DIN 02478501 · $0.4742 Jamp Silodosin · DIN 02539519 · $0.4742 PMS-Silodosin · DIN 02517779 · $0.4742 Sandoz Silodosin · DIN 02475421 · $0.4742
Shortage status: discontinued (November 10, 2021, reported by ALLERGAN INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02361663
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since December 6, 2021 — choose a marketed DIN from the same-category list.

Rapaflo · DIN 02361671 · 8 mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-11-11 — choose a marketed DIN from the same-category list.Discontinued November 11, 2022 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-11-11 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-11-11 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 351, 352
Reason for Use code 351 For the management of benign prostatic hyperplasia where six weeks of treatment with other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have been ineffective. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 352 For the management of benign prostatic hyperplasia where other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have produced intolerable side effects. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Rapaflo · DIN 02361671 Manufacturer: Watson Laboratories Inc.; listing date 2013-02-28 Health Canada: Cancelled post market since 2022-11-11 · brand RAPAFLO · ATC G04CA04 SILODOSIN · form Capsule · route Oral · ingredients SILODOSIN 8 MG · company Allergan inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Rapaflo: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02361671)

Source record
DIN 02361671: Rapaflo Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 920000679; group id 961; item number 2282; lccId 00229; manufacturer id WAT Source form: Cap; strength: 8mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02361671 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84674
Interchangeable products
Auro-Silodosin · DIN 02478528 · $0.4742 Jamp Silodosin · DIN 02539527 · $0.4742 PMS-Silodosin · DIN 02517787 · $0.4742 Sandoz Silodosin · DIN 02475448 · $0.4742
Shortage status: discontinued (October 31, 2022, reported by ALLERGAN INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02361671
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since November 11, 2022 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (G04C, G04CA): coverage varies; not interchangeable

  • Tamsulosin (Flomax CR Tab): general benefit, not a benefit
  • Alfuzosin (Xatral): limited Use 351, 352
  • Dutasteride (Avodart): limited Use 384, 385
  • Finasteride (Propecia): limited Use 384, 385, not a benefit
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

TAMSULOSIN HCL

· 10 products · General benefit (9), Listed, not a benefit (1) · strengths: 0.4mg · ER Cap

ALFUZOSIN HYDROCHLORIDE

· 6 products · Limited Use, codes 351, 352 · strengths: 10mg · Prolong-Rel Tab

DUTASTERIDE

· 12 products · Limited Use, codes 384, 385 · strengths: 0.5mg · Cap

FINASTERIDE

· 23 products · Off-Formulary Interchangeable, not an ODB benefit (8), Limited Use, codes 384, 385 (15) · strengths: 1mg, 5mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: the signs and symptoms of benign prostatic hyperplasia
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. ALFUZOSIN HYDROCHLORIDE · Limited Use, codes 351, 352 INDICATIONS AND CLINICAL USE XATRAL (alfuzosin hydrochloride) is indicated for:  Benign Prostatic Hyperplasia XATRAL is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).  Acute Urinary Retention XATRAL is indicated as adjunctive therapy with urethral catheterization for Acute Urinary Retention related to BPH and management following catheter removal. PM: https://pdf.hres.ca/dpd_pm/00049054.PDF; date January 2, 2019; DIN 02245565; fetched 2026-09-10 Product monograph TADALAFIL · Off-Formulary Interchangeable, not an ODB benefit (72), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) CIALIS is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). PM: https://pdf.hres.ca/dpd_pm/00037181.PDF; date not captured; DIN 02248088; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Sandoz Silodosin (silodosin) is indicated for:  The treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Geriatrics (≥ 65 years of age): Silodosin has been found to be safe and effective when administered at therapeutic doses (8 mg once daily) to patients over the age of 65 years (see CLINICAL TRIALS section). Pediatrics (< 18 years of age): The safety and effectiveness of silodosin in pediatric patients have not been established. Sandoz Silodosin is not indicated for use in children (see WARNINGS AND PRECAUTIONS section). Women: The safety and effectiveness of silodosin in female patients have not been established. Sandoz Silodosin is not indicated for use in women (see WARNINGS AND PRECAUTIONS section). https://pdf.hres.ca/dpd_pm/00060987.PDF PM date: May 14, 2021 Source product: SANDOZ SILODOSIN; DIN 02475421; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Rapaflo · DIN 02361663 Shortage status: discontinued (2021-11-10, reported by ALLERGAN INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02361663

Check this DIN again

Rapaflo · DIN 02361671 Shortage status: discontinued (2022-10-31, reported by ALLERGAN INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02361671

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Rapaflo: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026